Cargando…

Leveraging Physiologically Based Modelling to Provide Insights on the Absorption of Paliperidone Extended-Release Formulation under Fed and Fasting Conditions

Paliperidone was approved by the US FDA in 2006 as an extended-release (ER) tablet (Invega(®)) for the once-daily treatment of schizophrenia. This osmotic-controlled release oral delivery system (OROS) offers advantages, such as the prevention of plasma concentration fluctuation and reduced dosing f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Subhani, Saima, Lukacova, Viera, Kim, Chaejin, Rodriguez-Vera, Leyanis, Muniz, Paula, Rodriguez, Monica, Cristofoletti, Rodrigo, Van Os, Sandra, Suarez, Elena, Schmidt, Stephan, Vozmediano, Valvanera
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959113/ https://www.ncbi.nlm.nih.gov/pubmed/36839950 http://dx.doi.org/10.3390/pharmaceutics15020629

Ejemplares similares

Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug–Drug Interactions of Phenytoin
por: Rodriguez-Vera, Leyanis, et al.
Publicado: (2023)

Model-Informed Optimization of a Pediatric Clinical Pharmacokinetic Trial of a New Spironolactone Liquid Formulation
por: Tatipalli, Manasa, et al.
Publicado: (2021)

Application of a dual mechanistic approach to support bilastine dose selection for older adults
por: Kim, Chaejin, et al.
Publicado: (2021)

Pharmacometrics, Physiologically Based Pharmacokinetics, Quantitative Systems Pharmacology—What's Next?—Joining Mechanistic and Epidemiological Approaches
por: Schmidt, Stephan, et al.
Publicado: (2019)

Model-Based Analysis of In Vivo Release Data of Levonorgestrel Implants: Projecting Long-Term Systemic Exposure
por: Kim, Soyoung, et al.
Publicado: (2023)

Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug‐Drug Interactions Using Physiologically Based Pharmacokinetic Modeling
por: Cicali, Brian, et al.
Publicado: (2020)

Treatment of bipolar mania with paliperidone extended-release
por: Kotorki, Paraskevi, et al.
Publicado: (2010)

Role of paliperidone extended-release in treatment of schizoaffective disorder
por: Canuso, Carla M, et al.
Publicado: (2010)

The role of paliperidone extended release for the treatment of bipolar disorder
por: Marino, Jehan, et al.
Publicado: (2012)

Effects of paliperidone extended release on the symptoms and functioning of schizophrenia
por: Huang, Min-Wei, et al.
Publicado: (2012)

Influencing Factors and Predictors of Early Response in Schizophrenia Patients Receiving the Paliperidone Extended-Release Tablets (Paliperidone ER)
por: Jung, Seung-Ho, et al.
Publicado: (2013)

PALIPERIDONE PALMITATE 6-MONTH FORMULATION FOR THE TREATMENT OF SCHIZOPHRENIA: A 4-MONTH FOLLOW-UP STUDY
por: Romero Guillena, S. L., et al.
Publicado: (2023)

Serum Concentrations of Paliperidone After Administration of the Long-Acting Injectable Formulation
por: Helland, Arne, et al.
Publicado: (2017)

Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation
por: Corbeil, Olivier, et al.
Publicado: (2022)

Paliperidone extended-release: does it have a place in antipsychotic therapy?
por: Gahr, Maximilian, et al.
Publicado: (2011)

Paliperidone extended release for the treatment of pediatric and adolescent patients with Tourette's disorder
por: Yamamuro, Kazuhiko, et al.
Publicado: (2014)

Safety and Efficacy of Paliperidone Extended-Release in Acute and Maintenance Treatment of Schizophrenia
por: Spina, Edoardo, et al.
Publicado: (2011)

Effects of paliperidone extended release on hostility among Thai patients with schizophrenia
por: Jariyavilas, Apichat, et al.
Publicado: (2017)

Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis
por: Kishi, Taro, et al.
Publicado: (2022)

Tolerability profile of paliperidone palmitate formulations: A pharmacovigilance analysis of the EUDRAVigilance database
por: Cicala, Giuseppe, et al.
Publicado: (2023)

Key Factors in Effective Patient-Tailored Dosing of Fluoroquinolones in Urological Infections: Interindividual Pharmacokinetic and Pharmacodynamic Variability
por: Estradé, Oskar, et al.
Publicado: (2022)

Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia
por: Turkoz, Ibrahim, et al.
Publicado: (2008)

Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoconjunctivitis or chronic urticaria
por: Rodríguez, Mónica, et al.
Publicado: (2020)

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
por: Nash, Abigail I, et al.
Publicado: (2019)

Comparison of Paliperidone Palmitate from Different Crystallization Processes and Effect on Formulations In Vitro and In Vivo
por: Shi, Junfeng, et al.
Publicado: (2022)

Mechanistic Oral Absorption Modeling and Simulation for Formulation Development and Bioequivalence Evaluation: Report of an FDA Public Workshop
por: Zhang, X, et al.
Publicado: (2017)

Ocular Physiologically Based Pharmacokinetic Modeling for Ointment Formulations
por: Le Merdy, Maxime, et al.
Publicado: (2020)

Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies
por: Markowitz, Michael, et al.
Publicado: (2013)

F230. COMPARISON OF PALIPERIDONE PALMITATE 3-MONTH AND PALIPERIDONE PALMITATE 1-MONTH FORMULATION FOR NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: A PHASE 3 NON-INFERIORITY STUDY
por: Mathews, Maju, et al.
Publicado: (2018)

The social functional outcome of being naturalistically treated with paliperidone extended-release in patients with schizophrenia
por: Nakagawa, Ryoko, et al.
Publicado: (2015)

Population Pharmacokinetics of Paliperidone Palmitate (Once‐Monthly Formulation) in Japanese, Korean, and Taiwanese Patients With Schizophrenia
por: Shimizu, Hiroko, et al.
Publicado: (2019)

Baseline risk characterization of early versus later adopters of long‐acting paliperidone palmitate formulations
por: Fife, Daniel, et al.
Publicado: (2022)

The Influence of Fed State Lipolysis Inhibition on the Intraluminal Behaviour and Absorption of Fenofibrate from a Lipid-Based Formulation
por: Braeckmans, Marlies, et al.
Publicado: (2022)

The effects of concurrent oral paliperidone or risperidone use with paliperidone long-acting injection
por: Stump, Trevor A., et al.
Publicado: (2021)

Treatment response, safety, and tolerability of paliperidone extended release treatment in patients recently diagnosed with schizophrenia
por: Helldin, Lars, et al.
Publicado: (2015)

Paliperidone extended-release tablets in Chinese patients with schizophrenia: meta-analysis of randomized controlled trials
por: Cai, Shangli, et al.
Publicado: (2015)

PM531. Population Pharmacokinetic/Pharmacodynamic Modeling of Paliperidone Palmitate 3-Month Formulation in Asian Population
por: Russu, Alberto, et al.
Publicado: (2016)

Efficacy of paliperidone palmitate 3-month formulation in preventing hospital admissions. 60 months of follow-up
por: Romero Guillena, S.L., et al.
Publicado: (2022)

Requirements, expectations, challenges and opportunities associated with training the next generation of pharmacometricians
por: Schmidt, Stephan, et al.
Publicado: (2023)

Comparative absorption of curcumin formulations
por: Jäger, Ralf, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_31848r36ce8n4qffdv2388tjur